Accesswire
15 Oct 2026, 20:35 UTC · 1h ago
Impact · against what's priced in
Vogenx has initiated a Phase 2b trial for mizagliflozin in post-bariatric hypoglycemia, a condition with no FDA-approved treatments. While the drug's general pipeline and safety profile were known, the formal start of this first-mover study provides a concrete path toward market entry.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Vogenx has initiated its Phase 2b EMERGE study of mizagliflozin for post-bariatric hypoglycemia (PBH) involving approximately 36 adults.
Newpress release dated October 15, 2026
So whatSuccessful results from this 28-day treatment period would position VOGX as the first-mover in a market with zero FDA-approved treatments.
More positive than 81% of claims this week
Continue reading
5 related stories
The initiation of the EMERGE Phase 2b study creates a potential first-mover advantage in the post-bariatric hypoglycemia market, which currently has zero FDA-approved treatments.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Mizagliflozin is being developed for three distinct indications: post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's Syndrome.
Priced inbackground description of lead product candidate
More positive than 57% of claims this week
Prior to the EMERGE study, mizagliflozin has been administered to more than 500 subjects across 10 clinical studies.
Priced inreference to prior clinical studies
So whatThe existing safety profile from 500+ subjects lowers the probability of unexpected serious adverse events during the Phase 2b trial.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 80% of ticker scores this week
The company has initiated a Phase 2b clinical trial for a first-in-class drug targeting a condition with no current FDA-approved treatments.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1d ago
—
VOGX hasn't traded since this ran. Last close $16.05 (Oct 15); the reaction starts at the next open.
VOGX chart →
